September 30, 2009 (Berlin, Germany) — Denosumab, a novel biologic product that targets bone, has shown efficacy in cancer patients with bone metastases, with results that rival those seen with the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA announced that denosumab has been ...

July 19, 2011 — The novel bone agent denosumab (Xgeva, Amgen) has been approved in all 27 member states of the European Union for use in adult patients with solid tumors and bone metastases. The ...

Please provide your email address to receive an email when new articles are posted on . Denosumab prevented more skeletal-related events than the standard of care zoledronic acid for patients with ...

Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases --Denosumab Trial Met Primary and All Secondary Endpoints by ...

The addition of denosumab to aromatase therapy results in a significant reduction in clinical fractures and yields benefits for disease-free survival in postmenopausal women with hormone ...

Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases --Denosumab Trial Met Primary and All Secondary Endpoints by ...

Amgen shares are likely to soar once the markets open in the USA later today after the company presented late-stage data showing the superiority of its experimental osteoporosis drug denosumab over ...

The Food and Drug Administration has approved Amgen's (AMGN) osteoporosis drug denosumab for use by cancer patients with solid tumors whose disease has metastasized to their bones. The indication to ...

Denosumab, a drug commonly used to treat osteoporosis and prevent bone complications in cancer patients, is being investigated for a potential new application in breast cancer treatment. Early results ...

Bone metastases cause patient morbidity and mortality. A recent study compared denosumab with zoledronic acid for the treatment of bone metastases in advanced breast cancer. Denosumab seemed to be the ...